Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)

Arrowhead Pharmaceuticals

Status and phase: Enrolling; Phase 3

Conditions: Hypertriglyceridemia

Treatments: Drug: Placebo; Drug: Plozasiran Injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT06347133

2023-509302-30 (EudraCT Number)

AROAPOC3-3009

Details and patient eligibility

About

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

Enrollment: 1,328 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Established diagnosis of hypertriglyceridemia (HTG) and prior documented evidence (medical history) of mean fasting TG level ≥150 mg/dL (≥1.69 mm/L) and ≤499 mg/dL (≤5.64 mmol/L)
• Mean fasting TG level ≥150 mg/dL (≥1.69 mmol/L) and ≤499 mg/dL (≤5.64 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
• Fasting low density lipoprotein-cholesterol (LDL-C) ≤ 130 mg/dL (≤3.37 mmol/L) at screening
• Screening HbA1c ≤8.5%
• Willing to follow diet counseling and maintain a stable low-fat diet
• Must be on standard of care lipid-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator)

Exclusion criteria

• Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of investigational drug and inclisiran must be separated by at least 4 weeks.
• Use of any other hepatocyte targeted siRNA or antisense Oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer
• Acute pancreatitis within 4 weeks prior to screening
• Body mass index >45 kg/m^2

Note: Additional Inclusion/Exclusion criteria may apply per protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,328 participants in 2 patient groups, including a placebo group

Plozasiran Injection

Experimental group

Description:

4 doses of plozasiran by subcutaneous (sc) injection

Treatment:

Drug: Plozasiran Injection

Placebo

Placebo Comparator group

Description:

calculated volume to match active treatment by sc injection

Treatment:

Drug: Placebo